MedTrace Logo

Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron

NCT05342818 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-10-20

No results posted yet for this study

Summary

One big problem in mechanically ventilated ICU patients is delayed gastric emptying. Delayed gastric emptying in these patients, causes intolerance and high gastric residual volume (GRV) that can lead to abdominal distention, vomiting, increased aspiration risk and consequently increased the length of hospital stay.

In this study, investigators will evaluate Neostigmine's effect in reducing GRV in mechanically ventilated patients and compare its effect with metoclopramide and Ondansetron

.

Conditions

  • Delayed Gastric Emptying

Interventions

DRUG

Neostigmine

will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs

DRUG

Ondansetron 8mg

will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs

DRUG

Metoclopramide Injection

will be given by infusion in 20 minutes once daily by a nurse blinded to the study drugs

OTHER

Enteral feeding nutrition

The type and rate of enteral feeding nutrition will be the same for all patients (180ml/3h). All patients have a 30-degree head-up position

OTHER

Sequential Organ Failure Assessment (SOFA) score

SOFA score will be performed on all patients before the beginning of the study

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • AHMED A SHAMA, MD · Lecturer and consultant of anesthesia and surgical ICU in Tanta University and Faculty of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2022-07-30
Completion
2022-10-17

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05342818 on ClinicalTrials.gov